Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial.
The fibroblast growth factor 23 (FGF23) response to phosphate load is suppressed in adiponectin gene null mice and substantially amplified in mice overexpressing the same gene and vitamin D receptor (VDR) activation markedly enhances FGF23 gene expression. We performed an analysis of the static (baseline adiponectin levels) and dynamic (fluctuations in adiponectin levels) interactions of serum adiponectin with the FGF23 response to paricalcitol and placebo in the setting of a double-blind, randomized clinical trial in chronic kidney disease (CKD) patients (NCT01680198). As compared with placebo, VDR activation by paricalcitol markedly increased serum FGF23 levels (P < 0.001), and such an increase was amplified in patients in the 4th adiponectin quartile as compared with other quartiles (P = 0.009) while no such an effect was noted in the placebo group (P = 0.49). Both baseline adiponectin (P for interaction = 0.009) and fluctuations in adiponectin levels following paricalcitol and placebo (P for interaction = 0.003) strongly modified the difference in the FGF23 response to these treatments. These interactions were specific because no similar effect modification by other factors with the FGF23 response to VDR activation was found. Furthermore, in a global correlation analysis, adiponectin and FGF23 were interrelated independent of the estimated glomerular filtration rate and other potential confounders (β = 0.22, P = 0.003). Adiponectin is a strong modifier of the FGF23 response to VDR activation in CKD patients. The adiponectin-FGF23 link discovered in genetically engineered mice is of mechanistic relevance in the FGF23 response to VDR activation in CKD patients.